Missing data on the estimation of the prevalence of accumulated human immunodeficiency virus drug resistance in patients treated with antiretroviral drugs in north america.

TitleMissing data on the estimation of the prevalence of accumulated human immunodeficiency virus drug resistance in patients treated with antiretroviral drugs in north america.
Publication TypeJournal Article
Year of Publication2011
AuthorsAbraham AG, Lau B, Deeks S, Moore RD, Zhang J, Eron J, Harrigan R, M Gill J, Kitahata M, Klein M, Napravnik S, Rachlis A, Rodriguez B, Rourke S, Benson C, Bosch R, Collier A, Gebo K, Goedert J, Hogg R, Horberg M, Jacobson L, Justice A, Kirk G, Martin J, McKaig R, Silverberg M, Sterling T, Thorne J, Willig J, Gange SJ
Corporate AuthorsNorth American AIDS Cohort Collaboration on Research and Design of the International Epidemiologic Databases to Evaluate AIDS
JournalAm J Epidemiol
Volume174
Issue6
Pagination727-35
Date Published2011 Sep 15
ISSN1476-6256
KeywordsAdult, Anti-HIV Agents, Drug Resistance, Multiple, Viral, Female, Follow-Up Studies, Genotype, HIV Infections, HIV-1, Humans, Male, Middle Aged, Mutation, North America, Prevalence, Retrospective Studies, Risk Assessment, RNA, Viral, Time Factors
Abstract

Determination of the prevalence of accumulated antiretroviral drug resistance among persons infected with human immunodeficiency virus (HIV) is complicated by the lack of routine measurement in clinical care. By using data from 8 clinic-based cohorts from the North American AIDS Cohort Collaboration on Research and Design, drug-resistance mutations from those with genotype tests were determined and scored using the Genotypic Resistance Interpretation Algorithm developed at Stanford University. For each year from 2000 through 2005, the prevalence was calculated using data from the tested subset, assumptions that incorporated clinical knowledge, and multiple imputation methods to yield a complete data set. A total of 9,289 patients contributed data to the analysis; 3,959 had at least 1 viral load above 1,000 copies/mL, of whom 2,962 (75%) had undergone at least 1 genotype test. Using these methods, the authors estimated that the prevalence of accumulated resistance to 2 or more antiretroviral drug classes had increased from 14% in 2000 to 17% in 2005 (P < 0.001). In contrast, the prevalence of resistance in the tested subset declined from 57% to 36% for 2 or more classes. The authors' use of clinical knowledge and multiple imputation methods revealed trends in HIV drug resistance among patients in care that were markedly different from those observed using only data from patients who had undergone genotype tests.

DOI10.1093/aje/kwr141
Alternate JournalAm. J. Epidemiol.
PubMed ID21813792
PubMed Central IDPMC3202147
Grant ListAHQ290-01-0012 / / PHS HHS / United States
AI-69432 / AI / NIAID NIH HHS / United States
AI-69434 / AI / NIAID NIH HHS / United States
CBR-86906 / / Canadian Institutes of Health Research / Canada
CBR-94036 / / Canadian Institutes of Health Research / Canada
HCP-97105 / / Canadian Institutes of Health Research / Canada
K01 AI071754 / AI / NIAID NIH HHS / United States
K01-AI071725 / AI / NIAID NIH HHS / United States
K01-AI071754 / AI / NIAID NIH HHS / United States
K23 EY013707 / EY / NEI NIH HHS / United States
K23-AI-61-0320 / AI / NIAID NIH HHS / United States
KRS-86251 / / Canadian Institutes of Health Research / Canada
M01-RR00071 / RR / NCRR NIH HHS / United States
M01-RR00079 / RR / NCRR NIH HHS / United States
M01-RR00083 / RR / NCRR NIH HHS / United States
M01-RR00722 / RR / NCRR NIH HHS / United States
MM01- RR025747 / RR / NCRR NIH HHS / United States
MO1-RR-00052 / RR / NCRR NIH HHS / United States
N02-CP55504 / CP / NCI NIH HHS / United States
P30 AI027763 / AI / NIAID NIH HHS / United States
P30 AI050410 / AI / NIAID NIH HHS / United States
P30-AI27757 / AI / NIAID NIH HHS / United States
P30-AI27767 / AI / NIAID NIH HHS / United States
P30-AI50410 / AI / NIAID NIH HHS / United States
P30-AI54999 / AI / NIAID NIH HHS / United States
R01-AA16893 / AA / NIAAA NIH HHS / United States
R01-DA04334 / DA / NIDA NIH HHS / United States
R01-DA11602 / DA / NIDA NIH HHS / United States
R01-DA12568 / DA / NIDA NIH HHS / United States
R01-MH54907 / MH / NIMH NIH HHS / United States
R24-AI067039 / AI / NIAID NIH HHS / United States
TGF-96118 / / Canadian Institutes of Health Research / Canada
U01-AA013566 / AA / NIAAA NIH HHS / United States
U01-AI069918 / AI / NIAID NIH HHS / United States
U01-AI31834 / AI / NIAID NIH HHS / United States
U01-AI34989 / AI / NIAID NIH HHS / United States
U01-AI34993 / AI / NIAID NIH HHS / United States
U01-AI34994 / AI / NIAID NIH HHS / United States
U01-AI35004 / AI / NIAID NIH HHS / United States
U01-AI35039 / AI / NIAID NIH HHS / United States
U01-AI35040 / AI / NIAID NIH HHS / United States
U01-AI35041 / AI / NIAID NIH HHS / United States
U01-AI35042 / AI / NIAID NIH HHS / United States
U01-AI35043 / AI / NIAID NIH HHS / United States
U01-AI37613 / AI / NIAID NIH HHS / United States
U01-AI37984 / AI / NIAID NIH HHS / United States
U01-AI38855 / AI / NIAID NIH HHS / United States
U01-AI38858 / AI / NIAID NIH HHS / United States
U01-AI42590 / AI / NIAID NIH HHS / United States
U01-AI68634 / AI / NIAID NIH HHS / United States
U01-AI68636 / AI / NIAID NIH HHS / United States
U01-HD32632 / HD / NICHD NIH HHS / United States
U10- EY08067 / EY / NEI NIH HHS / United States
U10-EY08052 / EY / NEI NIH HHS / United States
U10-EY08057 / EY / NEI NIH HHS / United States
UL1-RR024131 / RR / NCRR NIH HHS / United States
Z01-CP010176 / CP / NCI NIH HHS / United States